MedTrace Logo

Bodewell Products for the Treatment of Atopic Dermatitis

NCT05566262 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-02

No results posted yet for this study

Summary

This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products

Conditions

Interventions

DRUG

Bodewell Calming Cream

Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Tiffany Mayo, MD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2027-02-28
Completion
2028-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566262 on ClinicalTrials.gov